111 related articles for article (PubMed ID: 4442446)
1. An evaluation of various antiparkinsonian agents as releasing agents and uptake inhibitors for 3H-dopamine in slices of rat neostriatum.
Orlansky H; Heikkila RE
Eur J Pharmacol; 1974 Dec; 29(2):284-91. PubMed ID: 4442446
[No Abstract] [Full Text] [Related]
2. A comparison of the inhibitory effects of certain antiparkinsonian agents on dopamine accumulation into the rat striatum.
Nose T; Segawa T
Jpn J Pharmacol; 1974 Apr; 24(2):299-305. PubMed ID: 4152745
[No Abstract] [Full Text] [Related]
3. Effects of benapyrzine, a new antiparkinson drug, on dopamine uptake into corpus striatum.
Palfreyman MG; Palfreyman ES; Clark MS
Eur J Pharmacol; 1974 Oct; 28(2):379-83. PubMed ID: 4418659
[No Abstract] [Full Text] [Related]
4. Amphetamine: evaluation of d- and l-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex.
Heikkila RE; Orlansky H; Mytilineou C; Cohen G
J Pharmacol Exp Ther; 1975 Jul; 194(1):47-56. PubMed ID: 1151755
[TBL] [Abstract][Full Text] [Related]
5. Effect of sodium, hemicholinium-3 and antiparkinson drugs on (14C)acetylcholine synthesis and (3H)choline uptake in rat striatal synaptosomes.
Guyenet P; Lefresne P; Rossier J; Beaujouan JC; Glowinski J
Brain Res; 1973 Nov; 62(2):523-9. PubMed ID: 4148552
[No Abstract] [Full Text] [Related]
6. The topographical distribution of serotoninergic terminals in the neostriatum of the rat and the caudate nucleus of the cat.
Ternaux JP; Héry F; Bourgoin S; Adrien J; Glowinski J; Hamon M
Brain Res; 1977 Feb; 121(2):311-26. PubMed ID: 832165
[TBL] [Abstract][Full Text] [Related]
7. Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action.
Coyle JT; Snyder SH
Science; 1969 Nov; 166(3907):899-901. PubMed ID: 5345207
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the electrically induced release of [3H]dopamine by serotonin from superfused rat striatal slices.
Westfall TC; Tittermary V
Neurosci Lett; 1982 Feb; 28(2):205-9. PubMed ID: 6280111
[TBL] [Abstract][Full Text] [Related]
9. The effect of ventromedial tegmental lesions on the disposition and biosynthesis of dopamine and serotonin.
Goldstein M; Battista AF; Anagnoste B; Ceasar PM; Fuxe K; Hökfelt T
Adv Biochem Psychopharmacol; 1974; 10():45-53. PubMed ID: 4211049
[No Abstract] [Full Text] [Related]
10. Evidence for a specific uptake of dopamine by dopaminergic terminals of the rat cerebral cortex.
Tassin JP; Thierry AM; Blanc G; Glowinski J
Naunyn Schmiedebergs Arch Pharmacol; 1974; 282(3):239-44. PubMed ID: 4277015
[No Abstract] [Full Text] [Related]
11. Evaluation of amantadine as a releasing agent or uptake blocker for H 3 -dopamine in rat brain slices.
Heikkila RE; Cohen G
Eur J Pharmacol; 1972 Nov; 20(2):156-60. PubMed ID: 4651205
[No Abstract] [Full Text] [Related]
12. Simultaneous real-time correlation of drug effects on dopamine efflux and uptake in rat striatal slices.
Davidson C; Stamford JA
Biochem Soc Trans; 1993 Nov; 21(4):483S. PubMed ID: 8132050
[No Abstract] [Full Text] [Related]
13. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
14. In vivo activation by benzotropine of dopamine release and synthesis in the caudate nucleus.
Cheramy A; Gauchy G; Glowinski J; Besson MJ
Eur J Pharmacol; 1973 Feb; 21(2):246-8. PubMed ID: 4696107
[No Abstract] [Full Text] [Related]
15. Studies on the distinction between uptake inhibition and release of (3H)dopamine in rat brain tissue slices.
Heikkila RE; Orlansky H; Cohen G
Biochem Pharmacol; 1975 Apr; 24(8):847-52. PubMed ID: 1125084
[No Abstract] [Full Text] [Related]
16. Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum.
Hunt P; Kannengiesser M; Raynaud J
J Pharm Pharmacol; 1974 May; 26(5):370-1. PubMed ID: 4152974
[No Abstract] [Full Text] [Related]
17. Morphine selectively blocks dopamine-stimulated cyclic AMP formation in rat neostriatal slices [proceedings].
Minneman KP; Iversen LL
Br J Pharmacol; 1977 Mar; 59(3):480P-481P. PubMed ID: 191131
[No Abstract] [Full Text] [Related]
18. Effects of amantadine and of some synthetic antiparkinsonian drugs on the behavioral response to L-DOPA in mice.
Florio V; Longo VG
Physiol Behav; 1971 Apr; 6(4):465-6. PubMed ID: 5148760
[No Abstract] [Full Text] [Related]
19. MK-801 prevents methamphetamine-induced striatal dopamine damage and reduces extracellular dopamine overflow.
O'Dell SJ; Weihmuller FB; Marshall JF
Ann N Y Acad Sci; 1992 May; 648():317-9. PubMed ID: 1637061
[No Abstract] [Full Text] [Related]
20. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
